推 auloveayumi:一次比一次簡陋...= =a 03/28 14:58
→ wuuuu:痾...我個人是覺得po上來好處多於壞處耶.. 03/28 19:44
推 jan1987ice:恩~這樣就不會浪費紙了~ 03/29 11:00
接下來論文的 abstract應該都只會po版
Purpose:
A multicenter double-blind, randomized, placebo controlled clinical trial was
performed to assess the effect of zoledronic acid, a potent new bisphosphonate,
on bone mineral density during androgen deprivation therapy for nonmetastatic
prostate cancer.
Materials and Methods:
Men with M0 (no distant metastases) prostate cancer beginning androgen
deprivation therapy were randomly assigned to receive 4 mg. zoledronic acid or
placebo intravenously every 3 months for 1 year. The primary efficacy variable
was the percent change from baseline to 1 year in bone mineral density of the
lumbar spine as measured by dual energy x-ray absorptiometry.
Results:
A total of 106 men were enrolled in the trial. Mean bone mineral density in the
lumbar spine increased by 5.6% in men receiving zoledronic acid and decreased
by 2.2% in those given placebo (mean difference 7.8%, 95% confidence interval
5.6%–10.0%, p <0.001). Mean bone mineral density of the femoral neck,
trochanter and total hip also increased in the zoledronic acid group and
decreased in the placebo group. Zoledronic acid was well tolerated.
Conclusions:
Zoledronic acid increases bone mineral density in the hip and spine during
androgen deprivation therapy for nonmetastatic prostate cancer.
KEYWORD:
diphosphonates, prostatic neoplasm, bone density, osteoporosis
--
※ 發信站: 批踢踢實業坊(ptt.cc)
◆ From: 61.64.103.47